These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 26677013)

  • 1. Survivin silencing and TRAIL expression using oncolytic adenovirus increase anti-tumorigenic activity in gemcitabine-resistant pancreatic cancer cells.
    Han Z; Lee S; Je S; Eom CY; Choi HJ; Song JJ; Kim JH
    Apoptosis; 2016 Mar; 21(3):351-64. PubMed ID: 26677013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reexpression of human somatostatin receptor gene 2 gene mediated by oncolytic adenovirus increases antitumor activity of tumor necrosis factor-related apoptosis-inducing ligand against pancreatic cancer.
    Zhang Z; Huang Y; Newman K; Gu J; Zhang X; Wu H; Zhao M; Xianyu Z; Liu X
    Clin Cancer Res; 2009 Aug; 15(16):5154-60. PubMed ID: 19671855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silencing Daxx increases the anti-tumor activity of a TRAIL/shRNA Bcl-xL-expressing oncolytic adenovirus through enhanced viral replication and cellular arrest.
    Kang S; Kang D; Bakhtiar Ul Islam SM; Je S; Kim JH; Song JJ
    Cell Signal; 2015 Jun; 27(6):1214-24. PubMed ID: 25748050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer.
    Jung KH; Choi IK; Lee HS; Yan HH; Son MK; Ahn HM; Hong J; Yun CO; Hong SS
    Cancer Lett; 2017 Jun; 396():155-166. PubMed ID: 28315430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of tumor suppressor TSLC1 by a survivin-regulated oncolytic adenovirus significantly inhibits hepatocellular carcinoma growth.
    He G; Lei W; Wang S; Xiao R; Guo K; Xia Y; Zhou X; Zhang K; Liu X; Wang Y
    J Cancer Res Clin Oncol; 2012 Apr; 138(4):657-70. PubMed ID: 22237452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Replication-competent adenovirus expressing TRAIL synergistically potentiates the antitumor effect of gemcitabine in bladder cancer cells.
    Mao L; Yang C; Li L; Nai L; Fan L; Wang J; Li W; Wen R; Chen J; Zheng J
    Tumour Biol; 2014 Jun; 35(6):5937-44. PubMed ID: 24604329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic Adenovirus Expressing ST13 Increases Antitumor Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Against Pancreatic Ductal Adenocarcinoma.
    Zhang Y; Ye M; Huang F; Wang S; Wang H; Mou X; Wang Y
    Hum Gene Ther; 2020 Aug; 31(15-16):891-903. PubMed ID: 32475172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIF-2α dictates the susceptibility of pancreatic cancer cells to TRAIL by regulating survivin expression.
    Harashima N; Takenaga K; Akimoto M; Harada M
    Oncotarget; 2017 Jun; 8(26):42887-42900. PubMed ID: 28476028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strong antitumor efficacy of a pancreatic tumor-targeting oncolytic adenovirus for neuroendocrine tumors.
    Yamamoto Y; Nagasato M; Rin Y; Henmi M; Ino Y; Yachida S; Ohki R; Hiraoka N; Tagawa M; Aoki K
    Cancer Med; 2017 Oct; 6(10):2385-2397. PubMed ID: 28941156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RGD-modified oncolytic adenovirus-harboring shPKM2 exhibits a potent cytotoxic effect in pancreatic cancer via autophagy inhibition and apoptosis promotion.
    Xu Y; Chu L; Yuan S; Yang Y; Yang Y; Xu B; Zhang K; Liu XY; Wang R; Fang L; Chen Z; Liang Z
    Cell Death Dis; 2017 Jun; 8(6):e2835. PubMed ID: 28569774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine.
    Bhattacharyya M; Francis J; Eddouadi A; Lemoine NR; Halldén G
    Cancer Gene Ther; 2011 Oct; 18(10):734-43. PubMed ID: 21836633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silencing of Mcl-1 overcomes resistance of melanoma cells against TRAIL-armed oncolytic adenovirus by enhancement of apoptosis.
    Tolksdorf B; Zarif S; Eberle J; Hazini A; Dieringer B; Jönsson F; Kreppel F; Kurreck J; Fechner H
    J Mol Med (Berl); 2021 Sep; 99(9):1279-1291. PubMed ID: 34028599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo.
    Leitner S; Sweeney K; Oberg D; Davies D; Miranda E; Lemoine NR; Halldén G
    Clin Cancer Res; 2009 Mar; 15(5):1730-40. PubMed ID: 19223497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic adenovirus mediated Survivin RNA interference and 5-fluorouracil synergistically suppress the lymphatic metastasis of colorectal cancer.
    Shen W; Tu JK; Wang XH; Fu ZX
    Oncol Rep; 2010 Nov; 24(5):1285-90. PubMed ID: 20878122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma.
    Wei RC; Cao X; Gui JH; Zhou XM; Zhong D; Yan QL; Huang WD; Qian QJ; Zhao FL; Liu XY
    Hum Gene Ther; 2011 Sep; 22(9):1109-19. PubMed ID: 21361790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting X-linked inhibitor of apoptosis protein inhibits pancreatic cancer cell growth through p-Akt depletion.
    Jiang C; Yi XP; Shen H; Li YX
    World J Gastroenterol; 2012 Jun; 18(23):2956-65. PubMed ID: 22736919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A hypoxia- and telomerase-responsive oncolytic adenovirus expressing secretable trimeric TRAIL triggers tumour-specific apoptosis and promotes viral dispersion in TRAIL-resistant glioblastoma.
    Oh E; Hong J; Kwon OJ; Yun CO
    Sci Rep; 2018 Jan; 8(1):1420. PubMed ID: 29362367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel CDC25B Promoter-Based Oncolytic Adenovirus Inhibited Growth of Orthotopic Human Pancreatic Tumors in Different Preclinical Models.
    Weber HL; Gidekel M; Werbajh S; Salvatierra E; Rotondaro C; Sganga L; Haab GA; Curiel DT; Cafferata EG; Podhajcer OL
    Clin Cancer Res; 2015 Apr; 21(7):1665-74. PubMed ID: 25573380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic antitumor effects of CDK inhibitor SNS‑032 and an oncolytic adenovirus co‑expressing TRAIL and Smac in pancreatic cancer.
    Ge Y; Lei W; Ma Y; Wang Y; Wei B; Chen X; Ru G; He X; Mou X; Wang S
    Mol Med Rep; 2017 Jun; 15(6):3521-3528. PubMed ID: 28440486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus.
    Dong F; Wang L; Davis JJ; Hu W; Zhang L; Guo W; Teraishi F; Ji L; Fang B
    Clin Cancer Res; 2006 Sep; 12(17):5224-30. PubMed ID: 16951242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.